Taysha, FDA agree on next steps of REVEAL trial for Rett gene therapy
Taysha Gene Therapies has reached an agreement with the U.S. Food and Drug Administration (FDA) on the design and next steps to start the pivotal Part B of its ongoing Phase 1/2 REVEAL trial program, which is evaluating TSHA-102 in children, adolescents, and adults with Rett syndrome.